Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors

(2009) Adrian Egli et al.   JOURNAL OF INFECTIOUS DISEASES

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE